Mpox

Mpox is an exotic infectious disease caused by the Mpox virus. The disease was first identified in laboratory monkeys, thus earning its name, but in its natural state, it seems to infect rodents more than primates. A fever, headache, muscle pains, swollen lymph nodes, and fatigue are the first symptoms in humans. After this, a rash forms with blisters and crusts. Symptoms typically appear 7 to 14 days after exposure. In most cases, symptoms last 2 to 4 weeks. Children, pregnant women, and people with suppressed immune systems are at greater risk of severe cases.

Human Monkeypox – Epidemiology, Clinical Characteristics, Diagnosis, and Prevention

The human monkeypox virus, which belongs to the genus Orthopoxvirus of the family Poxviridae, is a DNA virus.

What is Monkeypox?

Monkeypox Epidemiology

Monkeypox 2003 U.S. Outbreak

Monkeypox; What is It and How Do We Treat It?

Latest Mpox News and Research

WHO Results Report 2024 shows progress on global health goals amid financial uncertainties

The World Health Organization (WHO) Results Report 2024, shows progress on global health goals, even in times of growing financial uncertainties.

12 May 2025

Celebrating 25 years of GOARN's global health impact

The Global Outbreak Alert and Response Network (GOARN), an initiative coordinated by the World Health Organization (WHO), marks its 25th anniversary today.

29 Apr 2025

Africa CDC and WHO strengthen mpox response with updated strategy

Africa CDC and WHO have updated their joint Continental Response Plan for the mpox emergency as the disease continues to affect new areas.

18 Apr 2025

Africa faces growing mpox threat amid foreign aid reductions

Foreign aid cuts could result in a major outbreak of mpox across the African continent and beyond, with virus control measures already disrupted, public health experts warn.

11 Apr 2025

Slashed federal funding cancels vaccine clinics amid measles surge

More than a dozen vaccination clinics were canceled in Pima County, Arizona.

9 Apr 2025

Mpox virus poses rising global epidemic and pandemic threat

Insufficient research on mpox hinders effective control strategies, emphasizing the need to understand its transmission and immune response mechanisms.

7 Apr 2025

Research highlights rising risk of human-to-human mpox transmission

Mpox has the potential to become a significant global health threat if taken too lightly, according to scientists at the University of Surrey.

1 Apr 2025

Artificial intelligence tool predicts virus outbreak hotspots

A new artificial intelligence tool could aid in limiting or even prevent pandemics by identifying animal species that may harbor and spread viruses capable of infecting humans.

31 Mar 2025

Registration Now Open for World Vaccine Congress Washington 2025: Leading Experts from Government, WHO, CEPI, and more to Speak

Register for the World Vaccine Congress 2025, the premier event for vaccine experts and leaders, driving innovations in public health and pandemic preparedness.

From World Vaccine Congress Washington 21 Mar 2025

Third International Health Regulations Emergency Committee meeting addresses mpox upsurge

The Director-General of the World Health Organization (WHO) is hereby transmitting the report of the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee (Committee) regarding the upsurge of mpox 2024, held on Tuesday, 25 February 2025, from 12:00 to 17:00 CET.

18 Mar 2025

Tecovirimat monotherapy found ineffective for treating clade II mpox in NIH-sponsored trial

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions.

12 Mar 2025

WHO Director-General issues revised recommendations on mpox emergency

The Director-General of the World Health Organization (WHO), following the third meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the upsurge of mpox 2024, held on 25 February 2025, from 12:00 to 17:00 CET, concurs with its advice that the event continues to meet the criteria of a public health emergency of international concern and, considering the advice of the Committee, he is hereby issuing a revised set of temporary recommendations.

27 Feb 2025

New mpox variant can spread rapidly across borders

International researchers, including from DTU National Food Institute, warn that the ongoing mpox outbreak in the Democratic Republic of the Congo (DRC) has the potential to spread across borders more rapidly.

20 Feb 2025

Study explains why tecovirimat fails against some mpox strains

A virus originally found in animals, mpox – which causes the disease of the same name – is now circulating in humans.

13 Feb 2025

Surge in violence in eastern Democratic Republic of the Congo leads to healthcare crisis

The recent surge in violence in the eastern Democratic Republic of the Congo has led to significant loss of life, trauma, displacement, and the destruction of critical health infrastructure, exacerbating an already dire situation for millions of people.

8 Feb 2025

Penn researchers develop optimized framework for COVID-19 vaccination distribution

Engineering and medical researchers at Penn have developed a groundbreaking framework that can determine the best and most computationally optimized distribution strategy for COVID-19 vaccinations in any given community.

22 Jan 2025

SHEA calls for continued U.S. partnership with the World Health Organization

The Society for Healthcare Epidemiology of America (SHEA) wants to emphasize the importance of global partnerships in addressing health threats that impact all of us, as Americans and global citizens. We urge President Trump to reconsider the decision to terminate the U.S. relationship with the World Health Organization (WHO).

21 Jan 2025

Predicting H5N1 disease severity based on T cell responses

New research led by scientists at La Jolla Institute for Immunology (LJI) suggests that many people already have immune cells on "stand by" to fight the H5N1 virus, also known as highly pathogenic avian influenza.

2 Jan 2025

New class of antivirals shows promise against multiple viruses

The arrival of Paxlovid in December 2021 marked another turning point in the COVID-19 pandemic - an effective antiviral that has since successfully treated millions.

11 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024